Cholebine (colestilan) / Mitsubishi Tanabe - LARVOL DELTA

Combined Use of Statin and PCSK9 Inhibitor in a Pregnant Woman with Possible Familial Hypercholesterolemia and Coronary Artery Stenosis. (PubMed, J Atheroscler Thromb) - "Although ezetimibe and colestimide were administered at 14 weeks, the target LDL-C level was not achieved. Thus, treatment with pravastatin was started at 23 weeks and evolocumab at 32 weeks of gestation...In conclusion, the combined use of statin and PCSK9 inhibitor could effectively manage LDL-C levels, and it might be a safe option during pregnancy. Nevertheless, further research is required to assess the safety and efficacy of this combination therapy during pregnancy."

Journal • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Metabolic Disorders

CHEMOPREVENTIVE EFFECT OF COLESTIMIDE, A BILE ACID BINDING RESIN, ON COLITIS-ASSOCIATED COLON TUMORIGENESIS IN MICE (DDW 2025) - "Additionally, no tumors were observed in animals that were not injected with azoxymethane. [Conclusion] This study demonstrates that Colestimide has a promising effect on the chemoprevention of colorectal carcinogenesis associated with chronic colitis."

Preclinical • Colon Cancer • Colorectal Cancer • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Oncology

Successful pregnancy outcome in a woman with cholesteryl ester storage disease treated with enzyme replacement therapy. (PubMed, J Clin Lipidol) - "Enzyme replacement therapy (ERT) using sebelipase alfa, a recombinant form of LAL, is effective in improving lipid profiles and reversing liver dysfunction in patients with CESD...Given the absence of CESD complications, colestimide was the only medication administered during pregnancy...Following delivery, transient triglycerides, low-density lipoprotein-cholesterol, and liver enzyme increases were observed. However, restarting ERT led to a gradual improvement in the liver function and lipid profile."

Journal • Atherosclerosis • Dyslipidemia • Hepatology • Liver Failure • Metabolic Disorders • Obstetrics

Cholestyramine in hemodialysis: a new approach for hyperphosphatemia management. (PubMed, Korean J Physiol Pharmacol) - P4 | "Cholestyramine is chosen for study in hemodialysis patients based on the effectiveness and safety of bile acid sequestrants such colestilan and colestipol in the treatment of hyperphosphatemia and hypercholesterolemia in hemodialysis patients. Median serum triglyceride and low-density lipoprotein cholesterol levels had decreased significantly versus baseline values in the cholestyramine group. Cholestyramine used with phosphate binders effectively lowers phosphorus levels, improves the lipid profile, and has mild adverse effects."

Journal • Cardiovascular • Chronic Kidney Disease • Dyslipidemia • Endocrine Disorders • Metabolic Disorders • Nephrology • Orthopedics • Renal Disease • Secondary Hyperparathyroidism

Involvement of bile acid in diarrhoea and therapeutic effect of colestimide in hereditary ATTR amyloidosis. (PubMed, Amyloid) - "Bile acid status was significantly associated with diarrhoea in ATTRv amyloidosis. Colestimide and other bile acid sequestrants may reduce diarrhoea frequency in afflicted patients."

Journal • Amyloidosis • Cardiac Amyloidosis

Bile Acid Sequestrants Based on Natural and Synthetic Gels. (PubMed, Gels) - "The chemical structures and methods of synthesis are shown for commercial BASs of first- (cholestyramine, colextran, and colestipol) and second-generation (colesevelam and colestilan) and potential BASs. Focus is given to the understanding of the relationships between the chemical structure of these cross-linked polymers and their potential to bind bile salts. The synthetic pathways used in obtaining BASs and their in vitro and in vivo hypolipidemic activities are also introduced."

Journal • Review • Dyslipidemia • Metabolic Disorders

Differential diagnosis of ulcerative colitis with increased diarrhea; collagenous colitis or irritable bowel syndrome? A case report. (PubMed, J Int Med Res) - "Histopathology of colonic biopsies revealed new-onset collagenous colitis (CC), with a thickened subepithelial collagen band (SECB) and inactive UC. We herein report the importance of random colonic biopsies to diagnose CC even when the endoscopic appearance of the colon is normal in patients with inflammatory bowel disease with worsened diarrhea."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis

Usefulness of colestimide for diarrhea in postoperative Crohn's disease. (PubMed, JGH Open) - "In the global clinical judgment, 13 and 4 patients in the ileocecal and non-ileocecal resection groups, respectively, were judged as "effective," with an overall efficacy rate of 70.8%. Colestimide is effective for diarrhea in patients with postoperative CD, especially after ileocecal resection."

Journal • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease • CRP

Clinical and genetic features of sitosterolemia in Japan. (PubMed, Clin Chim Acta) - "We are providing a demographic overview of the clinical and genetic backgrounds of Japanese patients with sitosterolemia."

Journal • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Immunology • Metabolic Disorders • Rheumatology

A case of COVID-19 diarrhea relieved by bile acid sequestrant administration. (PubMed, Clin J Gastroenterol) - "The oral administration of a bile acid sequestrant, colestimide, improved his diarrhea quickly...It decreases bile acid absorption at the distal ileum and increases colonic delivery of bile acids, resulting in bile acid diarrhea. In summary, the clinical course of the case presented in this report suggests that bile acid diarrhea is a possible mechanism of watery diarrhea observed in patients with coronavirus disease 2019."

Journal • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

Usefulness of colestimide for postoperative refractory diarrhea in patients with Crohn's disease (AOCC 2021) - No abstract available

Clinical • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

The Rising Risk of Chronic Kidney Disease (CKD) and How it is Dealt With: A Review of Current and Potential Phosphate Binders (PB). (PubMed, Mini Rev Med Chem) - "Lanthanum carbonate seemed to lower all-cause mortality and reduce the chance of hypercalcemia, even though a deposit in the GI tract was observed. Colestilan, like sevelamer, lowered LDL cholesterol...Bixalomer appeared to have fewer gastrointestinal side effects than sevelamer. Nano-lanthanum hydroxide and SBR759 may have an interesting future as PBs. In conclusion, the development of new PBs should also take into consideration their potential to function as protection modifiers."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Metabolic Disorders • Nephrology • Renal Disease • FGF23

Cardiovascular mortality in chronic kidney disease patients: potential mechanisms and possibilities of inhibition by resin-based phosphate binders. (PubMed) - "In addition, they reduce serum LDL-C, inflammation, uric acid and high Hba1c values. These differences suggest that not all phosphate binders may be equal in the context of cardiovascular mortality in this patient population."

Journal • Biosimilar • Chronic Kidney Disease • Diabetes • Dyslipidemia • Immunology • Inflammation • Renal Disease

Enterohepatic Circulation of Bile Acids Is Activated by Bariatric Surgery before Weight Loss Becomes Apparent (ADA 2018) - "The increase in plasma BA was suppressed by administration of one of bile acid sequestrants, colestimide. These changes led to alteration of gut microbiota in DJB rats, and the resting core body temperature of DJB rats was increased over that of sham-operated rats from 2 weeks after surgery. Therefore, elevation of plasma BA levels early after bariatric surgery by activation of de novo BA synthesis and enterohepatic circulation may play an important role in postoperative metabolic improvement and weight loss."

Biosimilar

Term use of colestimide is effective against hyperglycemia and overweight in patients with type 2 diabetes (ADA 2011) - Presentation time: June 25, 2011: 11:30 AM - 1:30 PM; P=NA, N=16; Findings suggest that long-term use of colestimide may also be effective against hyperglycemia & overweight as well as hypercholesterolemia in pts with type 2 DM; Its administration could be beneficial for diabetic pts complicated with obesity & high cholesterol level

Dyslipidemia

Bile acid sequestrant Colestilan improves peripheral insulin sensitivity by increasing fatty acid flux from fat tissue to biliary lipids in high-fat fed APOE*3- LEIDEN mice - Colestilan improves peripheral insulin sensitivity in high-fat fed E3L mice by decreasing visceral obesity via increased flux of FFAs from adipose tissue to the liver for the synthesis and excretion of biliary lipids

Preclinical-animal • Dyslipidemia

Phosphate binders in chronic kidney disease: an updated narrative review of recent data. (PubMed, J Nephrol) - "For this narrative review a PubMed searched was undertaken to identify new publications on phosphate binders that had been published between January 2015 and July 2019. The present review summarizes this most recent information on dietary measures and their problems in treating hyperphosphatemia in CKD patients, overall effects of phosphate binders on cardiovascular mortality and morbidity, adherence to phosphate binder therapy as well as new data on specific aspects of the various phosphate binders on the market: calcium-containing phosphate binders, polymeric phosphate binders (sevelamer, bixalomer, colestilan), magnesium-containing phosphate binders, lanthanum carbonate, ferric citrate, sucroferric oxyhydroxide, and new compounds in development, in particular drugs targeting intestinal phosphate transporters."

Journal • Review

Comparative Efficacy and Safety of Phosphate Binders in Hyperphosphatemia Patients With Chronic Kidney Disease. (PubMed, JPEN J Parenter Enteral Nutr) - "Iron-based phosphate-binding agents were the preferable agents when considering efficacy and safety simultaneously."

Clinical • Journal